A B S T R A C T Aluminum salts have been used as vaccine adjuvants for > 50 years, and they are currently present in at least 146 licensed vaccines worldwide. In this study we examined whether adsorption of Army Liposome Formulation (ALF) to an aluminum salt that already has an antigen adsorbed to it might result in improved immune potency of the aluminum-adsorbed antigen. ALF is composed of a family of anionic liposome-based adjuvants, in which the liposomes contain synthetic phospholipids having dimyristoyl fatty acyl groups, cholesterol and monophosphoryl lipid A (MPLA). For certain candidate vaccines, ALF has been added to aluminum hydroxide (AH) gel as a second adjuvant to form ALFA. Here we show that different methods of preparation of ALF changed the physical structures of both ALF and ALFA. Liposomes containing the saponin QS21 (ALFQ) have also been mixed with AH to form ALFQA as an effective combination. In this study, we first adsorbed one of two different antigens to AH, either tetanus toxoid conjugated to 34 copies of a hapten (MorHap), which has been used in a candidate heroin vaccine, or gp140 protein derived from the envelope protein of HIV-1. We then co-adsorbed ALF or ALFQ to the AH to form ALFA or ALFQA. In each case, the immune potency of the antigen adsorbed to AH was greatly increased by co-adsorbing either ALF or ALFQ to the AH. Based on IgG subtype and cytokine analysis by ELISPOT, ALFA induced predominately a Th2-type response and ALFQ and ALFQA each induced more balanced Th1/Th2 responses.
Introduction
Vaccine formulation technology involves a complex interplay between the antigen, which forms the template for a complementary specific immune response, and the innate immune system which is programmed to amplify the reaction of the body to potential danger from a threat [1] . A central factor in the creation of a vaccine often includes the inclusion of an adjuvant which serves as a mechanism for initiating innate immunity [2, 3] . In some instances, the adjuvant itself can also help to direct the specificity of the immune response [4] . Particulate materials per se can sometimes have inherent adjuvant activity [5, 6] , and the architectural structures and chemical compositions of particles can add chemical, physical, and immunological complexity to the adjuvant. Aluminum salts are an example of a family of popular adjuvants, mainly comprising aluminum hydroxide (AH), aluminum phosphate, or potassium aluminum sulfate (alum) particles [7] [8] [9] .
Aluminum salts, because of their low cost and perceived safety, have been utilized as adjuvants for many types of vaccines. In a 1992 publication from the US Food and Drug Administration it was reported that 33 licensed vaccines in the United States contained aluminum salt [10] . In a comprehensive analysis of stability data for licensed vaccines in 2012, the compositions of at least 146 licensed vaccines worldwide were described as containing an aluminum salt adjuvant [11] . Although aluminum salts possess extremely complex mineralogical properties [7, 12] , they have a record of reasonable safety in humans. Two examples of aluminum-adjuvanted vaccines are Engerix-B®, a vaccine that comprises recombinant hepatitis B surface antigen adsorbed to aluminum hydroxide [13] , and Gardasil®, a vaccine that comprises a viruslike protein (VLP) nanoparticle from human papilloma virus (HPV) adsorbed to amorphous aluminum hydroxyphosphate sulfate [14] .
Aluminum salts are relatively modest stimulants of immunity in humans, and are used mainly only for the induction of antibodies. However, because aluminum salts consist of relatively large microparticles [9] , they provide potential landing zones for simultaneous adsorption of both antigens and nanoparticles which can provide opportunities for further immunostimulation by inclusion of additional adjuvants. For example, adsorption of monophosphoryl lipid A (MPLA) micelles to aluminum salt (a combination known as adjuvant system 04, or AS04) has strengthened certain types of vaccines [15] . Two such commercial formulations that have led to enhanced adaptive immunity include Fendrix®, which contains both MPLA and recombinant hepatitis B surface antigen adsorbed to aluminum phosphate [16] , and Cervarix®, which contains both MPLA and VLPs from HPV adsorbed to aluminum hydroxide (AH) [17] .
An often noted and unpleasant, but generally tolerable, side effect either of an aluminum salt or of MPLA micelles as an adjuvant is the occurrence of local pain, swelling, and irritation at the injection site. The combination of both MPLA micellar particles and aluminum salt with antigen in the form of AS04, either with Fendrix® or Cervarix®, resulted in greater injection site pain when compared to vaccines containing aluminum salt alone (i.e., with Engerix-B® or Gardasil®) [18] [19] [20] [21] . It seems reasonable to presume that the increased side effects observed were caused by the presence of MPLA. Although MPLA is wellknown as a type of bacterial endotoxin and is associated with pyrogenicity and many other toxic adverse biological reactions, all of the side effects of MPLA are essentially eliminated by incorporation of MPLA in liposomes having phospholipids with dimyristoyl fatty acyl groups, and the formulation also causes a markedly enhanced immune response [22, 23] . This type of non-toxic and potent liposomal adjuvant is referred to as Army Liposome Formulation (ALF) [24] [25] [26] .
The remarkable penetration of world vaccine markets by vaccines containing antigens adsorbed to aluminum salt adjuvants caused us to hypothesize in this study that the immune response to a vaccine containing an antigen adsorbed to an aluminum salt might be further improved by co-adsorbing ALF to the aluminum as an additional adjuvant. In order to examine this without causing dilution of either the aluminum or its adsorbed antigen, we determined whether an aqueous suspension of ALF nanoparticles (ALFwet) could be lyophilized and then reconstituted by adding either a buffer solution or an aqueous suspension of aluminum particles containing a pre-adsorbed protein antigen. After reconstitution, the resultant suspension is referred to as ALFlyo or ALFlyoA, respectively. In the course of this work we discovered that ALFlyo consists of a diverse population of unique unilamellar particles ranging in size from nano to micro. The complexities and immunostimulant properties of the various ALF-type particles mixed only with free antigen, or adsorbed to aluminum particles containing adsorbed antigen, are described.
Materials and methods

Materials and reagents
Dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), synthetic cholesterol (Chol), and all synthetic monophosphoryl lipid A derivatives (MPLA) (native MPLA, PHAD®, 3D-PHAD®, and 3D(6-acyl)-PHAD® were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Alhydrogel®, a sterilized AH wet gel suspension, pH 5-7, was purchased from Brenntag (Frederikssund, Denmark). QS21was purchased from Desert King International (San Diego, CA, USA). Tetanus Toxoid (TT) was purchased from Statens Serum Institut (Copenhagen, Denmark). MorHap [N-((4R,4aR,7R,7aR,12bS)-9-hydroxy-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano-benzofuro[3,2-e]isoquinolin-7-yl)-3-mercaptopropanamide] was synthesized at NIDA, NIH, and kindly provided by Dr. Kenner C Rice. MorHap was coupled to TT as previously described [27] . The TT-MorHap conjugate used in this study had a molar ratio of 
Preparation of liposomes
DMPC and Chol were dissolved in chloroform; DMPG and MPLA (either PHAD®, 3D-PHAD®, 3D-(6acyl)-PHAD®, or native MPLA, as indicated) were dissolved in chloroform:methanol (9:1). Each lipid stock solution was prepared in freshly distilled chloroform. QS21 stock solutions (1 mg/ml) were made in Sorensen's phosphate-buffered saline (PBS) (pH 5.6). Alhydrogel® stock (10 mg/ml) was diluted to 1 mg aluminum/ml in Dulbecco's PBS (DPBS) (pH 7.4). Lipids in organic solvents were mixed, dried with rotary evaporation followed by overnight vacuum. Liposomes were formed and microfluidized either in DPBS (ALFwet); or liposomes, formed by dispersion in water, were microfluidized, then lyophilized, and then reconstituted in DPBS (ALFlyo). Lyophilization was performed with a VirTis Advantage EL (SP Industries, Warminster, PA, USA) as described previously [32] , with modifications of the lyophilization program as follows: 4 h at −60°C, 4 h at −40°C, 4 h at −20°C, 4 h at −10°C, 8 h at 0°C, 10 h at 10°C, all under 100 mbar vacuum. ALFQ was prepared as previously described [24] , except that Sorensen's PBS (pH 6.2) was used rather than DPBS (pH 7.4). Liposomal DMPC and DMPG were in a molar ratio of 9:1. Liposomal Chol was either 43 mol% or 55 mol% when compared to the phospholipids in ALF or ALFQ, respectively. After preparation, the liposomes were subjected to Chol analysis as previously described [24] . The molar ratio of total phospholipid:3D-PHAD® was 8.8:1 (ALF, ALFA), or 88:1 (ALFQ, ALFQA). Both the concentrations of phospholipid (2.29 mM or 22.9 mM with respect to water) and the amount of liposomal MPLA (20 μg per injection dose) were constant in each mouse immunization study. For fluorescent microscopy, liposomes were labelled by inclusion of Texas Red-DHPE (0.25% of total phospholipids) (Thermo Fisher Scientific, Waltham, MA, USA).
Preparation of vaccines and immunization of mice
For immunization with antigen adsorbed to AH, the antigen, either TT-MorHap or CN54 gp140, as indicated, was added to AH for 30 min at 4°C. This was followed by addition of AH to the ALFwet, lyophilized ALFwet, or ALFQ for 30 min at 4°C to form either ALFwetA, ALFlyoA, or ALFQA, where indicated. In the absence of AH, the antigen was mixed directly with an aqueous suspension of ALFwet, ALFlyo, or ALFQ. The amount of TT-MorHap or CN54 gp140 antigen in each formulation was 10 μg per injection.
For immunization with TT-MorHap or gp140, female Balb/c mice from Jackson Laboratories (Bar Harbor, ME, USA), 6-7 weeks of age, were injected IM with 50 μl of vaccine formulation alternatively in different legs on weeks 0, 3, and 6. Terminal bleeding was at week 9 for animals vaccinated with gp140, or at week 14 for animals vaccinated with TT-MorHap. When the gp140-immunized animals were terminally bled, spleens were also collected.
Three different types of immunization experiments were performed. In one type of experiment, five formulations with TT-MorHap as the antigen were employed: 1) TT-MorHap + ALFlyo; 2) TTMorHap + ALFwet; 3) TT-MorHap + AH, followed by addition of lyophilized ALFwet to the AH to form ALFlyoA; 4) TT-MorHap + AH, followed by addition of ALFwet to the AH to form ALFwetA; 5) TTMorHap + AH. In a second type of experiment, seven vaccine formulations with HIV gp140 antigen were used: 1) gp140 + ALFlyo; 2) gp140 + ALFwet; 3) gp140 + AH, followed by addition of lyophilized ALFwet to the AH to form ALFlyoA; 4) gp140 + AH, followed by addition to ALFwet to form ALFwetA; 5) gp140 + ALFQ; 6) gp140 + AH, followed by mixture with ALFQ to form ALFQA; and 7) gp140 + AH. In a third type of experiment, four different formulations with HIV gp140 antigen were made with ALF containing different types of MPLA: 1) ALFwet (containing PHAD®) mixed with gp140; 2) ALFwet (containing 3D-PHAD®) mixed with gp140; 3) ALFwet (containing 3D-(6acyl)-PHAD ®) mixed with gp140; 4) ALFwet (containing native MPLA) + gp140.
ELISA
MorHap and TT ELISAs were performed as described earlier [27] . HIV capture antigens (0.1 μg in 0.1 ml DPBS) were added to Immulon 2HB round bottom plates (CN54 gp70 or gp120), or to Nunc MaxiSorp flat bottom plates (CN54 gp140, V3) (Thermo Fisher Scientific), followed by incubation at 4°C, overnight. Unbound antigen was removed and 200 μl of DPBS (pH 7.4) with 0.5% milk-0.1% Tween 20 (blocking buffer) was added at RT overnight. Serum samples were diluted in blocking buffer starting at 1:400 in serial 2-fold dilutions. One hundred μl of each sample was added to the plate in triplicate and the plate was incubated at RT for 1 h; washed 4 times with DPBS/0.5% Tween 20. HRP-conjugated anti-mouse secondary IgG (0.1 μg in 0.1 ml blocking buffer) was added and the plates were incubated for 1 h, followed by washing. Substrate (ABTS® 2-Component Microwell Peroxidase Substrate, Seracare, Gaithersburg, MD, USA) (0.1 ml/well) was added and the plate was incubated for 1 h. Color development was stopped by adding 100 μl/well of 1% sodium dodecyl sulfate. Absorbance was read at 405 nm on a Spectramax M2 Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). End point titer was defined as the dilution at which the absorbance was twice the background.
IgG subclass analysis
IgG subtype analysis was modified from Beck et al. [25] as follows. One hundred μl of goat anti-mouse IgG Fab in DPBS were added to 96-well Immulon 2HB flat bottom plates and incubated overnight at 4°C. Plates were blocked with 250 μl/well of blocking buffer (lacking Tween), and incubated at RT for 2 h. After blocking, 100 μl of blocking buffer were added to each well. Purified mouse IgG1, IgG2a, or IgG2b was diluted two-fold starting from 1 μl/ml in blocking buffer. One hundred μl of each dilution were added to the plates. Plates were incubated at RT for 1 h, and washed 3× with 0.05% Tween 20 in DPBS (washing buffer). One hundred μl of HRP-linked goat anti-mouse IgG1, IgG2a, and IgG2b (1:1000 dilution in blocking buffer) were added to the corresponding wells, and plates were incubated at RT for 1 h. Plates were washed and 100 μl of ABTS were added. Color development was stopped by adding 100 μl/well of 1% SDS. Absorbance was read at 405 nm. For subclass analysis, pooled mouse sera of each group was added to gp140-coated plates as for the standard ELISA. HRP-linked goat anti-mouse IgG1, IgG2a, or IgG2b was added and the ELISA was conducted together with the standard curve. Development was stopped by 100 μl/well of 1% SDS solution, and read at 405 nm. Concentrations of IgG subclasses were made from standard curves made with unconjugated goat anti-mouse IgG (Fab).
ELISPOT
Spleens were processed and ELISPOT and analysis was conducted as before [25] . The frequencies of IFN-γ and IL-4-producing cells were determined with a BioReader 3000 ELISPOT Reader (Bio-Sys GmbH, Karben, Germany). Data are expressed as the mean of number of spots per 400,000 cells ( ± SEM).
Microscopy
For light microscopy, samples of ALF and ALFA in DPBS were prepared as wet mounts and viewed in bright field at 500× magnification with an Olympus BH2-RFCA microscope with an Olympus DP71 camera. For confocal fluorescence microscopy, the total phospholipid concentration was 2.29 mM. Images were taken with a Zeiss LSM 710 confocal microscope (Zeiss, Oberkochen, Germany) using a 63×/1.4 Oil DIC Plan Apo. All images were processed with the Zeiss Zen 2012 Lite software. For electron microscopy, liposomes were adsorbed onto carbon-coated grids (Electron Microscopy Sciences Inc., Hatfield, PA, USA) and negatively stained with 2% uranyl acetate (Electron Microscopy Sciences Inc.). Electron micrographs were taken on a JEM-1400 transmission electron microscope (JEOL USA, Peabody, MA, USA) with magnification, as indicated.
Dynamic light scattering (DLS) and NanoSight nanoparticle tracking
The hydrodynamic diameter was determined by intensity of dynamic light scattering for ALFwet and ALFlyo at a concentration of 2.29 mM with a Malvern Zetasizer Nano S (Malvern, Worcestershire, UK) equipped with a 633 nm laser. Average size, particle distribution and concentration of a 1/200 dilution of ALFwet or a 1/25 dilution of ALFlyo were also determined with a NanoSight NS 300 (Malvern, Worcestershire, UK) nanoparticle tracking system equipped with a 532 nM laser.
Statistical analysis
Initial experiments with gp140 used 6 mice (Fig. 4) ; however, later experiments used 10 mice to achieve greater statistical power (Figs. 3, 5, 7, 8) . Each immunization was repeated for confirmation of the results, and each figure illustrates one of the two experiments. The single immunization experiment with TT-MorHap used 10 mice (Figs. 3 and  5 ). Statistical analysis was performed with GraphPad Prism software. Statistical comparison between multiple groups was performed using one-way ANOVA with Tukey's multiple comparison test. Comparison of different groups was performed using unpaired t-test with Welch's correction.
Results
Structures of ALFwet and ALFlyo
Comparisons were made between aqueous suspensions of microfluidized ALF (ALFwet) and ALFwet that had been lyophilized and then re-hydrated (ALFlyo). ALFwet vesicles had diameters of approximately 55-100 nm as visualized by electron microscopy after negative staining (Fig. 1A) . In contrast, ALFlyo contained a wide range of small to large (> 300 nm) particles (Fig. 1B) . Phase contrast light microscopy revealed that ALFlyo also had a range of very large particles, even as large as 30,000 nm in some cases, which appeared to be unilamellar or paucilamellar vesicles (Fig. 1C) . Dynamic light scattering analysis confirmed both the narrow size distribution of small particles in ALFwet (Fig. 1D ) and the presence of very large particles in ALFlyo (Fig. 1E) . However, the large particles in ALFlyo obscured and prevented detection of small particles by DLS. Size distributions of ALFwet and ALFlyo provided by NanoSight technology (Fig. 1F and G) correlated more reliably than DLS, within the size limits shown, with the distributions observed directly by visual methods (Fig. 1B-C) . The larger particles in ALFlyo were formed by cannibalization of the smaller particles of the lyophilized ALFwet; and this resulted in reduction of the total number of particles present in ALFlyo. Fig. 1F and G show the concentration and the size distribution of the particles after 1:200 (ALFwet) and 1:25 (ALFlyo) dilution. In order to calculate the total particle numbers in the original undiluted formulations, the particle counts of the diluted ALFwet and ALFlyo shown in Fig. 1F and G have to be multiplied by 200 and 25, respectively. Based on this, ALFwet had a 20-fold greater number of total particles than ALFlyo.
Effects of adsorption of ALF to aluminum hydroxide gel
ALFwet and ALFlyo, each of which had been labelled with Texas Red-DHPE were adsorbed to aluminum hydroxide gel (AH), resulting in particles which are referred to in the present context as ALFwetA and ALFlyoA. In each case, large clumps of AH-adsorbed labelled liposomes occurred, with smaller clumps of ALFwet ( Fig. 2A) than ALFlyoA (Fig. 2B) . Free (unadsorbed) fluorescent liposomes are shown as a control (Fig. 2C) , but free unadsorbed liposomes were not observed in Figs. 2A or B. 3.3. Adjuvant effects of ALFwet, ALFlyo, ALFwetA, and ALFlyoA for induction of antibodies to TT-MorHap or gp140
When TT-MorHap was mixed as a free antigen with ALFwet or ALFlyo as an adjuvant, equivalent titers of specific antibodies either to MorHap or TT were induced either with ALFwet or ALFlyo as an adjuvant (Fig. 3A) . However, in each case the titers induced to MorHap were approximately 10-fold higher than to TT. In contrast to TTMorHap, when gp140 was used as an antigen and mixed with ALFwet as an adjuvant, higher titers of antibodies to gp140 were induced than those obtained by mixing gp140 with ALFlyo as an adjuvant (Fig. 3A) .
TT-MorHap or gp140 was adsorbed to AH as an adjuvant, and then added either to ALFwet, or ALFwetA, or ALFlyoA, respectively. Immunization with each of these formulations then resulted either in greater than two-fold increases in antibody titers both to MorHap and TT (p < 0.05), or greater than three-fold increases in antibody titers to gp140 (p < 0.001) and cross-reactivity to gp120 (p < 0.001) 
(E)
. DLS detected only large particles in ALFlyo because of shadowing of the small particles (E). However, EM, light microscopy, and Nanosight technology revealed the wider particle distribution in ALFlyo. To measure the size distribution and particle numbers by Nanosight, ALFwet was diluted 200-fold and ALFlyo was diluted 25-fold to reach the optimal particle numbers per frame. F and G show the particles in the diluted samples. 
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From the above, we conclude that depending on the antigen employed, mixing of the free antigen with ALFlyo may or may not be equivalent to mixing with ALFwet as an adjuvant. However, when the antigen is adsorbed to AH, co-adsorption of either ALFwet or ALFlyo as a second adjuvant to form a two adjuvant formulation, namely ALFwet or ALFlyo + AH, results in significantly higher potency to the either TTMorHap or gp140.
It was also noted that the titers of IgG antibodies induced to gp140, or cross-reacting antibodies to gp120, were not dependent on the type or chemical structure of MPLA that was present in the ALF. No significant differences were observed between three synthetic MPLA compounds (PHAD®, 3D-PHAD®, 6A3D-PHAD®) or native MPLA (which contains several native MPLA congeners) (Fig. 4) .
IgG subtypes to TT-MorHap or gp140 adsorbed to ALF, AH, or ALFA
Analysis of IgG subtypes in pooled antisera revealed that adsorption of TT-MorHap or gp140 to AH resulted mainly in IgG1 antibodies to MorHap, or TT, or gp140, respectively, with very little IgG2a (Fig. 5) . In Balb/C mice IgG1 is a hallmark of the Th2 pathway, while IgG2a and IgG2b are hallmarks of the Th1 pathway. In each case, addition of ALFwet or ALFlyo to the AH containing the adsorbed antigen, resulted in a more balanced IgG1 and IgG2a response, with less but still appreciable amounts IgG2b. However, it was also noted in each case, but especially for gp140, ALFwet or ALFwetA consistently induced a larger fraction of IgG2a than that induced by ALFlyo.
Effects of addition of ALF containing QS21 to aluminum salt
ALF-type preparations having > 50% Chol and also containing both QS21 and MPLA are referred to as ALFQ. Because QS21 binds essentially irreversibly to Chol, and even forms pores in the liposomal bilayer, the cytotoxic effects of QS21 are detoxified by the liposomes but the adjuvant effect is retained [24, 25] . Negatively stained electron microscopy of ALFQ revealed vesicles covered with black dots that likely represent the sites of Chol-associated indentations or pores (Fig. 6A) . Transmission electron microscopy of ALFQ bound to aluminum hydroxide gel (AH) showed extensive adsorption of ALFQ to AH, resulting in a formulation now referred to as ALFQA (Fig. 6B) . The AH component of ALFQA had an amorphous plate-like appearance, which suggests that it had been converted at least in part to aluminum Fig. 3 . Magnitude of immune responses by vaccines using ALFwet, ALFlyo, ALFwetA, ALFlyoA, and AH. A) Immune responses to MorHap, TT, gp140 and gp120 induced by TTMorHap and gp140 vaccines, respectively, using free immunogens mixed with ALFwet and ALFlyo. ALFwet mixed with free antigen induced significantly higher IgG titer to gp140 and gp120 than ALFlyo. There were no significant differences in IgG titers to MorHap and TT between ALFwet and ALFlyo groups. B) Immune responses induced by vaccines using aluminum-adsorbed immunogens mixed with ALFwet and ALFlyo. Adding liposomal adjuvants to aluminum-adsorbed immunogen significantly increased the antibody titers to each capture antigen. Data are shown as mean ± SEM of titers to the immunizing antigens. p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). Fig. 4 . Comparison of adjuvanticity of ALF containing each of four different MPLA constructs for inducing antibodies to gp140. Data are shown as mean ± SD of titers to the immunizing antigen gp140 (A) and cross-reactivity of the antisera to gp120 (B). There were no significant differences between any of the bars.
phosphate through hydroxyl-phosphate ligand exchange [7] .
The induction of antibodies to gp140 by ALFQ and ALFQA resulted in a wide range of titers and cross-reactivities of antibodies with gp120, and the V3 loop of gp120, and gp70-V1V2 (Fig. 7) . The mean titers of antibodies to gp140 adsorbed to AH, and cross-reactivity with gp120 and V3 loop, but not with gp70-V1V2, were significantly enhanced by co-adsorption of ALFQ to AH (ALFQA).
IgG subtypes to TT-MorHap and gp140 adsorbed to AH, ALFQ, AH, or ALFQA
Adsorption of gp140 to AH, followed by addition of ALFQ to form ALFQA, resulted in an increase of IgG2a and IgG2b when compared to adsorption of gp140 only to AH (Fig. 8) . Mixing of gp140 to ALFQ in the absence of AH resulted in even higher amounts of IgG2a and IgG2b when compared to IgG1.
Cytokines induced by ALFA, ALFQ, and ALFQA
When compared with splenocytes from naïve controls, ELISPOT analysis of splenocytes from animals immunized with gp140 adjuvanted with ALFwetA and ALFlyoA elicited IL-4-positive cells in similar amounts, but with few or no IFN-γ-positive cells (Fig. 9) . Substantial numbers of both IL-4-positive and IFN-γ-positive cells were observed after adjuvanting with either ALFQ or ALFQA (Fig. 9 ).
Discussion
During the many decades that have elapsed since the introduction of aluminum salts as adjuvants for vaccines, two important principles have become clear, namely that aluminum salts are complex minerals that can occur as crystalline or amorphous structures; and they can exert adjuvant activities through numerous mechanisms and there is no requirement for any interaction with toll-like receptors [12, 33] .
Liposomal adjuvants created in different ways can also have different physical structures. For example, here we found that an aqueous suspension of small unilamellar ALF vesicles (ALFwet) comprised a homogeneous distribution of small (ca. 30-100 nm) unilamellar vesicles (Fig. 1A, D, and F) . In contrast, when the aqueous suspension of ALF was lyophilized to form a dried powder and then reconstituted by adding an aqueous buffer (ALFlyo), a broad and heterogeneous size distribution of a smaller number of particles was produced, ranging from 30 to 30,000 nm (Fig. 1B, C, E, and G) . Each of the larger ALFlyo liposomes had to be formed by cannibalization of many of the lyophilized ALFwet liposomes, resulting in a 20-fold reduction in total number of ALFlyo liposomes compared to ALFwet liposomes. A fascinating aspect of ALFlyo is that all or most of the liposomes that were formed appeared to be unilamellar (Fig. 1C) . The mechanism of the formation of large unilamellar vesicles from small unilamellar vesicles is not yet clear. However, although ALFwet and ALFlyo each contained a different number and size range of particles, because the same total number of lipid molecules were present in total population of ALFwet and ALFlyo particles, and because both types of particles were unilamellar, the total surface area of each type of formulation would be expected to be similar or identical.
In the course of this work, we compared the immune response obtained either after adding antigen directly to ALFwet, or with a formulation obtained by first reconstituting lyophilized ALFwet to form ALFlyo, and then mixing it with an antigen. When TT-MorHap was used as the antigen, ALFwet and ALFlyo each served equivalently as a potent adjuvant to induce specific antibodies both to TT and MorHap. However, the endpoint titers to MorHap were approximately ten-fold higher than the titers to TT (Fig. 3A) . It was previously found that when increased numbers of MorHap were conjugated to TT, the titers of anti-TT decreased while anti-MorHap titers remained high [27] . In the present case, each MorHap-TT antigen contained 34 copies of MorHap, and each of the haptens presumably served as a separate identical immunogenic epitope. In contrast, the TT portion of the conjugate presented smaller numbers of individual immunogenic epitopes, many of which were obscured by the conjugated MorHap. From this, we conclude that when the macromolecular protein conjugate antigen (TTMorHap) was introduced into antigen presenting cells (APCs), the titers of specific antibodies to each individual immunogenic epitope depended on the number of copies of that individual epitope on the macromolecule that were present inside the APCs.
In contrast to TT-MorHap, endpoint titers to gp140 from mice immunized with gp140 that was adjuvanted with ALFwet were higher (700,000) than those in mice adjuvanted with ALFlyo (150,000) (p < 0.001) (Fig. 3A) . The reason for this differential effect between ALFwet and ALFlyo as an adjuvant, which was observed with gp140 but not with TT-MorHap, is unknown, but it might have related to incorporation of the gp140 molecules, both as encapsulated and transmembrane molecules in ALFlyo during the reconstitution process, in addition to surface-bound molecules. This might have altered or hindered or reduced the number of important immunogenic epitopes, such as conformational epitopes, in gp140 but not in TT-MorHap. The extremely complex differences of structures and numbers of ALFlyo particles when compared to ALFwet, together with the different types of associations with antigenic protein, makes direct comparisons of the adjuvanticity of the two types of particles difficult to predict when used alone with different protein antigens.
As noted in the Introduction, at least 146 vaccines worldwide contain an antigen adsorbed to an aluminum salt adjuvant [11] . A major goal of this study was to determine whether co-adsorption of ALF or ALFQ to an aluminum salt containing an adsorbed antigen might result in a more potent vaccine for the purpose of induction of antibodies. As a proof of principle, we utilized two different antigens, TT-MorHap or gp140, each of which was adsorbed to AH. In each case, as shown in Figs. 3B and 7, after addition of either ALF or ALFQ to the AH which contained adsorbed antigen, immunization of mice resulted in a higher titer of antibodies. In addition, based on antibody subtype analyses in Figs. 5 and 7, the relative Th1 response (IgG2a and IgG2b) compared to Th2 response (IgG1) was changed by the different types of formulations.
From a manufacturing standpoint, two different types of ALF were utilized, namely ALFwet or ALFlyo. The ALFwet, when added to a suspension of AH-adsorbed antigen, would have the potential disadvantage of causing a dilution of both the AH and the antigen adsorbed to the AH; in contrast, utilizing the aqueous AH that contains pre-adsorbed antigen to reconstitute ALFwet to form ALFlyo would result in no dilution of the AH or its adsorbed antigen. ALF co-adsorbed to aluminum salt containing pre-adsorbed antigen (ALFA), or ALFQ, or the combination of ALFQ with aluminum hydroxide (ALFQA), each was previously used as an adjuvant in two experimental vaccines that resulted in strong immune responses and protected mice against infection with malaria [34, 35] .
From the present study, we conclude that it could be feasible to improve the titers of antibodies induced by certain licensed aluminumadjuvanted vaccines by hydration of ALFlyo with the aqueous vaccine suspension containing an aluminum-adsorbed antigen. As an alternative procedure, the pre-formulated licensed vaccine could be mixed with ALFwet to produce ALFwetA, and the injection dose might then be increased to compensate for the dilution. The end result in each case could be a more potent vaccine containing two particulate adjuvant compositions rather than one. As an additional potential benefit to utilization of this type of ALFA formulation, it is anticipated that, depending on the antigen, some Th1-type effects might be added to the original Th2-type of aluminum-adjuvanted vaccine. Further studies are planned to test these hypotheses by adding ALF to commercially available aluminum-adjuvanted vaccines. Because of the elimination of the toxicity of MPLA achieved by incorporation of ALF-type liposomes [22, 23] , adsorption of ALF to aluminum would not be expected to add further reactogenicity beyond that observed with aluminum salt alone [36] .
